The European Commission Has Adopted A Positive Decision For The Designation Of Agios Pharmaceuticals' Mitapivat As An Orphan Medicinal Product For Sickle Cell Disease

Benzinga · 07:03

. Earlier, in November 2020, the U.S. Food and Drug Administration (FDA) also granted orphan drug designation to mitapivat for sickle cell disease.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

The European Commission Has Adopted A Positive Decision For The Designation Of Agios Pharmaceuticals' Mitapivat As An Orphan Medicinal Product For Sickle Cell Disease

Risk Disclaimer